UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
---------------
SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
(Amendment No. 1)
---------------
SHAMAN PHARMACEUTICALS, INC.
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
819319 10
(CUSIP Number)
William D. Savoy Gail J. Gordon
Vulcan Ventures Incorporated Foster Pepper & Shefelman PLLC
110-110th Avenue N.E., Suite 550 1111 Third Avenue, Suite 3400
Bellevue, WA 98004 Seattle, WA 98101
(206) 453-1940 (206) 447-4400
(Name, Address and Telephone Number of Persons Authorized to Receive Notices and
Communications)
January 31, 2000
(Date of Event which Requires Filing of This Statement)
---------------
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of ss.ss. 240.13d-1(e), 240.13d-1(f) or 240.13nd-1(g), check
the following box. |_|
Note: Schedules filed in paper format shall include a signed original and five
copies of the schedule including all exhibits. See ss.240.13d-7 for other
parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
- -------------------------- ------------------------
CUSIP NO. 819319 10 13D Page 2 of 7 Pages
---------
- -------------------------- ------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Vulcan Ventures Incorporated
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |_|
(b) |_|
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(E)
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
State of Washington
- --------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES 0 shares
BENEFICIALLY ----------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH 3,674,476 shares(1)
REPORTING ----------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 0 shares
----------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
3,674,476 shares(1)
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,674,476(1)
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
11.9%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------
- ---------------
(1) Directly owned by Vulcan Ventures Incorporated. Paul G. Allen is the sole
shareholder of Vulcan Ventures Incorporated and may be deemed to have shared
voting and dispositive power with respect to such shares.
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
- -------------------------- ------------------------
CUSIP NO. 819319 10 13D Page 3 of 7 Pages
---------
- -------------------------- ------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Paul G. Allen
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |_|
(b) |_|
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
AF
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(E)
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States of America
- --------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES 0 shares
BENEFICIALLY ----------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH 3,674,476 shares(1)
REPORTING ----------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 0 shares
----------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
3,674,476 shares(1)
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,674,476 shares(1)
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
11.9%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IN
- --------------------------------------------------------------------------------
- ---------------
(1) Directly owned by Vulcan Ventures Incorporated. Paul G. Allen is the sole
shareholder of Vulcan Ventures Incorporated and may be deemed to have shared
voting and dispositive power with respect to such shares.
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
Introductory Note
- -----------------
This Amendment No. 1 (the "Amendment") amends and supplements the statement
on Schedule 13D, filed by Vulcan Ventures Incorporated and Paul G. Allen on
January 27, 2000, relating to the common stock, $0.001 par value per share (the
"Common Stock"), of Shaman Pharmaceuticals, Inc., a Delaware corporation (the
"Issuer"). Except as otherwise stated, amounts set forth in this statement
reflect a one-for-fifty reverse split of the outstanding Common Stock as of the
close of business on January 31, 2000 and the automatic conversion of each share
of the Issuer's Series R Stock into 31 shares of Common Stock (on a post-reverse
split basis) on February 1, 2000.
Only those items amended are reported herein. Capitalized terms not defined
herein have the meaning ascribed to them in the Schedule 13D.
Item 5. Interest in Securities of the Issuer
- ------- ------------------------------------
On February 1, 2000, the 110,263 shares of Series R Stock held of record by
Vulcan Ventures automatically converted into 3,418,153 shares of Common Stock.
Therefore, as of the date hereof, Vulcan Ventures owns of record and
beneficially 20,000 shares of the Issuer's Series C Stock and 3,418,153 shares
of Common Stock. In addition, assuming exercise of Warrants originally
exercisable for shares of the Issuer's Series R Stock and now exercisable for
shares of Common Stock at a price of $0.497 per share until August 23, 2002,
Vulcan Ventures may be deemed to own an additional 258,323 shares of Common
Stock. Therefore, the aggregate number of shares of Common Stock that Vulcan
Ventures may be deemed beneficially to own is 3,676,476 shares, representing
approximately 11.9% of the Common Stock outstanding as of February 1, 2000. This
percentage is based upon 30,491,643 shares of Common Stock outstanding as of
February 1, 2000, as reported to Vulcan Ventures by the Issuer. (That number is
subject to upward adjustment for rounding in connection with the Issuer's
reverse split as of January 31, 2000 and the automatic conversion of the Series
R Stock.) The Issuer's Certificate of Incorporation prohibits conversion of the
Series C Preferred to the extent such conversion would cause the holder's
beneficial ownership of Common Stock to exceed 4.9% of the outstanding shares of
Common Stock. Therefore, the shares of Common Stock into which the Series C
Stock held by Vulcan Ventures is convertible are not deemed beneficially owned
by Vulcan Ventures or Mr. Allen.
As the sole shareholder of Vulcan Ventures, Mr. Allen shares voting and
dispositive power with Vulcan Ventures over the shares of the Issuer's capital
stock owned by Vulcan Ventures. Therefore, Mr. Allen may be deemed the
beneficial owner of such shares.
To the best knowledge of Vulcan Ventures and Mr. Allen, none of the other
parties named in Item 2 owns any of the Issuer's common stock.
Since the date on which the Schedule 13D was filed, Vulcan Ventures and Mr.
Allen have sold an aggregate of 5,459,812 shares pre-reverse split of Common
Stock in over-the-counter transactions at the following pre-reverse split
prices:
----------------- ------------------------- -----------------------
Number of Shares of Gross Sales
Date Common Stock Price Per Share
----------------- ------------------------- -----------------------
1/28/99 200,000 .0990
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
60,000 .1090
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
140,000 .1100
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
185,000 .1150
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
40,000 .1180
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
55,000 .1200
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
10,000 .1250
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
100,000 .1260
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
10,000 .1270
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
200,000 .1300
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
400,000 .1350
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
100,000 .1400
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
200,000 .1480
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
1/31/00 250,000 .0590
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
250,000 .0600
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
509,812 .0610
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
150,000 .0625
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
100,000 .0640
----------------- ----------------- ------- -------------- --------
Page 4 of 7
<PAGE>
----------------- ----------------- ------- -------------- --------
250,000 .0680
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
150,000 .0700
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
100,000 .0720
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
750,000 .0740
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
500,000 .0750
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
250,000 .0760
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
100,000 .0780
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
150,000 .0790
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
220,000 .0800
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
10,000 .0900
----------------- ----------------- ------- -------------- --------
----------------- ----------------- ------- -------------- --------
20,000 .0950
----------------- ----------------- ------- -------------- --------
Except as set forth in this statement, Vulcan Ventures and Mr. Allen have
not, nor, to the knowledge of Vulcan Ventures has any of its executive officers,
directors or controlling persons, effected any transactions in the Issuer's
common stock during the past sixty days.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to
Securities of the Issuer.
- ------- ------------------------------------------------------------------------
Except as set forth in this statement, Vulcan Ventures and Mr. Allen do not
have, nor, to the knowledge of Vulcan Ventures does any of the executive
officers, directors or controlling persons of Vulcan Ventures have, any
contracts, arrangements, understandings or relationships (legal or otherwise)
with any person with respect to any securities of the Issuer, finder's fees,
joint ventures, loan or option agreements, puts or calls, guarantees of profits,
division of profits or loss, or the giving or withholding of proxies.
Item 7. Material To Be Filed as Exhibits.
- ------- --------------------------------
Exhibit Description
------- -----------
99.1 Joint Filing Agreement (Incorporated by reference to
the Reporting Persons' Schedule 13D filed January 27,
2000 with respect to the Issuer's securities.)
99.2 Power of Attorney filed on August 30, 1999, with the
Schedule 13G of Vulcan Ventures, Incorporated and
Paul G. Allen for Pathogenesis, Inc. (Incorporated
herein by reference.)
Page 5 of 7
<PAGE>
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
VULCAN VENTURES INCORPORATED
February 2, 2000 By: /s/ William D. Savoy
----------------------------------------
William D. Savoy, Vice President
February 2, 2000 *
-------------------------------------------
Paul G. Allen
*By: /s/ William D. Savoy
---------------------------------------
William D. Savoy as Attorney-in Fact for
Paul G. Allen pursuant to a Power of
Attorney filed on August 30, 1999, with
the Schedule 13G of Vulcan Ventures,
Incorporated and Paul G. Allen for
Pathogenesis, Inc. and incorporated herein
by reference.
Page 6 of 7
<PAGE>
EXHIBIT INDEX
Exhibit Description
99.1 Joint Filing Agreement (Incorporated by reference to
the Reporting Persons' Schedule 13D filed January 27,
2000 with respect to the Issuer's securities.)
99.2 Power of Attorney filed on August 30, 1999, with the
Schedule 13G of Vulcan Ventures, Incorporated and
Paul G. Allen for Pathogenesis, Inc. (Incorporated
herein by reference.)
Page 7 of 7
